STAT
NOVEMBER 4, 2024
This is Part 5 of “Behind the Counter,” an in-depth video series demystifying the complex world of patents and drug pricing. When patents for name brand medicines expire, the price of that medicine drops significantly as generic versions enter the market. Lower prices are good news for patients seeking more affordable medications, but the change can sometimes take a while.
PharmaVoice
NOVEMBER 5, 2024
Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioPharma Dive
NOVEMBER 6, 2024
Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.
pharmaphorum
NOVEMBER 8, 2024
Eisai has scaled down its sales expectations for Alzheimer's disease drug Leqembi after sluggish sales growth in the first half of the current fiscal year.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
NOVEMBER 7, 2024
For months, as human cases of H5N1 bird flu associated with an outbreak of the virus in U.S. dairy cattle have mounted, one question has loomed larger than others: how many human infections are getting missed? Farmworkers face some of the most intense exposure to the bird flu virus, but resistance from farmers and a lack of health insurance and paid sick leave in the industry have limited the amount of testing of workers and hampered public health officials’ ability to track where the vir
PharmaVoice
NOVEMBER 8, 2024
Past comments hint at the changes Robert F. Kennedy Jr. could make across the various sectors of healthcare.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
pharmaphorum
NOVEMBER 6, 2024
Two players in medical extended reality (XR) – XRHealth and NeuroReality – have come together in a quest to build the biggest company in the sector.Boston, US-based XRHealth is leading the deal, acquiring NeuroReality of the Netherlands for an undisclosed sum, combining their products and expertise in the use of XR and virtual reality software for healthcare applications.
STAT
NOVEMBER 6, 2024
The executive in charge of AstraZeneca operations in China is under detention by Chinese authorities who are investigating employees there, the company said. The disclosure comes after AstraZeneca last week acknowledged that Leon Wang, an executive vice president who also oversees international operations for the drugmaker, was being investigated along with a “small number” of employees.
PharmaVoice
NOVEMBER 6, 2024
After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 diabetes therapy.
BioPharma Dive
NOVEMBER 5, 2024
The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other tests, although Wall Street analysts were divided on how the two drugs compare.
Advertisement
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
pharmaphorum
NOVEMBER 5, 2024
AstraZeneca's shares have fallen more than 8% on speculation about an anti-corruption probe in China, its second-largest market, wiping around $14 billion off its value.The sell-off appears to have been prompted by an article in Chinese financial media outlet Yicai which suggested that "dozens of senior executives" at AZ's Chinese subsidiary have been implicated in an ongoing insurance fraud case.
STAT
NOVEMBER 5, 2024
A patient with sickle cell disease died while participating in a clinical trial of a CRISPR-based treatment from Beam Therapeutics, threatening to overshadow early signals of effective gene editing. Beam said the patient succumbed to respiratory failure, deemed to be “likely caused” by a regimen of chemotherapy required to prepare the patient for BEAM-101, a treatment that uses the company’s new, more precise form of CRISPR gene editing called base editing.
FDA Law Blog: Biosimilars
NOVEMBER 6, 2024
By Sara W. Koblitz — The fight between Jazz, Avadel, and FDA over narcolepsy drug sodium oxybate has been a long and arduous one. Starting in 2022 with a patent certification requirement, both Jazz and Avadel have sued FDA over this drug, with Jazz most recently bringing suit challenging FDA’s decision that Avadel’s Lumryz (sodium oxybate) is clinically superior to Jazz’s Xywav (sodium oxybate) in 2023.
BioPharma Dive
NOVEMBER 5, 2024
The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.
Speaker: Joe Sharpe and James Carlson
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
pharmaphorum
NOVEMBER 7, 2024
Discover the key takeaways from a webinar focused on boosting recruitment and retention through Social Determinants of Health (SDOH) data. Learn how incorporating SDOH data can enhance your recruitment and retention strategies.
STAT
NOVEMBER 4, 2024
One ad shows two older men talking jovially on a front porch, “Vietnam veteran” visible on one of their hats. Another shows an older man in military regalia, arms crossed, smiling proudly at the camera. Under names like “Patriot Plan,” “Courage MA,” and “Honor” plan, all of the major private Medicare insurers are courting veterans directly, selling plans that their ads say complement their Veterans Affairs coverage with benefits like
Med Ed 101
NOVEMBER 3, 2024
There are two agents that are frequently used in alcohol use disorder. Acamprosate and naltrexone have distinct advantages and disadvantages in the treatment of alcohol use disorder. In this article, we will compare the clinical benefits and risks of acamprosate vs naltrexone. What do the guidelines say? Both naltrexone and acamprosate are considered first-line treatments […] The post Acamprosate vs Naltrexone – Clinical Comparison appeared first on Med Ed 101.
BioPharma Dive
NOVEMBER 7, 2024
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Now, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
NOVEMBER 8, 2024
AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities
STAT
NOVEMBER 8, 2024
WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization.
European Pharmaceutical Review
NOVEMBER 6, 2024
Dupixent (dupilumab) has been approved by the European Medicines Agency (EMA) as the first treatment for young children with eosinophilic esophagitis in the EU. This authorisation is based on Phase III data which found that 68 percent of children aged one to 11 years given Dupixent (dupilumab) achieved histological disease remission at 16 weeks. This result was maintained for up to one year.
Pharmaceutical Technology
NOVEMBER 6, 2024
The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor optimism improved following the interest rate cuts by the US Federal Reserve in September 2024.
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
pharmaphorum
NOVEMBER 5, 2024
Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.Shares in the company gained almost 24% after it announced that the end of phase 2 meeting with the US regulator had firmed up plans for a phase 3 trial of bitopertin in EPP, as well as the potential for accelerated approval.
STAT
NOVEMBER 7, 2024
Dear Readers, If you’re reading this, you have likely received letters from me before, highlighting STAT’s coverage of health and medicine and appealing to you to consider becoming a subscriber. I’m here to do so again. This time, though, feels different: We are at a unique moment in our country’s history, when an understanding of the issues that STAT covers is more relevant than ever before — to both our personal lives and our professional lives.
Express Pharma
NOVEMBER 6, 2024
OmniActive Health Technologies (OmniActive) has announced its acquisition of ENovate Biolife (ENovate), a developer of clinically researched botanical ingredients. The transaction, financed through internal accruals, is expected to strengthen OmniActive’s position in delivering scientifically validated health ingredients to consumers worldwide. OmniActive, backed by TA Associates, has advanced encapsulation technologies to enhance ingredient solubility, stability, and bioavailability.
The Pharmacist
NOVEMBER 7, 2024
Exclusive Two-thirds of community pharmacists have been negatively impacted by GP collective action to some extent, a survey by The Pharmacist has suggested. But just 13% of practice and primary care network (PCN) pharmacists have felt a negative effect. This comes as our sister title Pulse reveals that 70% of GPs in England are engaging […] The post Two-thirds of community pharmacists 'negatively impacted' by GP action appeared first on The Pharmacist.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
NOVEMBER 7, 2024
Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.The Danish group bought rights to ocedurenone, an oral non-steroidal mineralocorticoid receptor antagonist (nsMRA), from the Singapore biotech in October 2023 as a companion to its GLP-1-based therapies for reducing cardiovascular risk and kidney disease in people with diabetes and obesity.
STAT
NOVEMBER 4, 2024
Researchers like to say that science is self-correcting, that knowledge is slowly but surely refined by new findings that build on or debunk old ones. But this process is far from perfect and is hampered by sloppy experiments or, in some cases, faked results. A small, tight-knit community of scientific sleuths has been unearthing growing evidence that many studies, including landmark papers published in top journals, contain manipulated images and falsified findings.
Express Pharma
NOVEMBER 4, 2024
Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk’s diabetes drug, liraglutide, to its platform in 2025. “We have already confirmed a core supplier for this addition and over the next few months expect to finish completing test and batch validation, as well as confirming certificates of analysis,” the company said.
The Pharmacist
NOVEMBER 4, 2024
Two in 10 patients think only GPs can treat minor ailments, a poll commissioned by the National Pharmacy Association (NPA) has suggested. And more than a third (36%) were unaware of the Pharmacy First service, the online polling of 2,052 UK adults found. The survey, carried out by Research without Barriers between 21 October and […] The post Poll reveals patient myths about antibiotics and minor ailments appeared first on The Pharmacist.
pharmaphorum
NOVEMBER 5, 2024
Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.The new capsule formulation of the antibiotic minocycline hydrochloride has been cleared by the US regulator to treat the inflammatory lesions caused by rosacea – which causes flushing or long-term redness and pustules on the face – in adults.
Expert insights. Personalized for you.
348 
Let's personalize your content